IOT Innovotech Inc

The Pest Management Regulatory Agency of Health Canada has granted Innovotech (TSV VENTURE: IOT) a Research Authorization for large-scale field trials for the 2009 season to test its novel seed treatment, Agress(TM). This Research Authorization provides growers with an opportunity to assess the real-world ability of Agress(TM) to fight bacterial disease and its ease of use. In conjunction with cooperating growers, dry beans treated with Agress(TM) have been planted on farms in Alberta.

"These large-scale field trials give us an opportunity to test Agress(TM) on a commercial scale that would be used by a grower," says Damian Sowa, Product Manager, Innovotech. "We will also use the trials to validate our small plot results that showed Agress(TM) to be a superior and long sought replacement for Streptomycin in bacterial infestations of beans."

Research is currently underway to expand the applications of AgressTM to include the major crops in North America and additional disease classes.

About Innovotech Inc:

Innovotech is a product development company focusing on the development of solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are protected communities of microorganisms which are very common and very difficult to treat due to their inherent resistance. The company currently has two products in advanced stages of development: bioFILM PA is a diagnostic kit which assists physicians in the selection of the most effective antibiotic treatment of patients with chronic lung infections. AgressTM is a novel seed treatment product which protects seeds during the critical germination and emergence stage from bacterial and fungal infection. Both products were developed against the corresponding organisms present as biofilms as opposed to the free-floating, planktonic form.

This document contains forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contacts: Innovotech Inc. Ken Boutilier President & CEO (780) 448-0585 ext 221 (780) 424-0941 (FAX) Email: ken.boutilier@innovotech.ca